Pub Date : 2023-07-15DOI: 10.18231/j.jpbs.2023.006
Anant R Kuchik, Rohit R Doke, Pranav P Bhor, Ritik R Matade, P. Gosavi, Akash R Shinde
This review focuses on the potential of nanotherapeutics in the diagnosis and treatment of neuronal abnormal conditions particularly epilepsy, alzheimer's disease (AD), and Parkinson's disease (PD). The advancements in nanotechnology have paved the way for the development of nanocarrier systems that can target the underlying pathogenesis of these diseases. The study aimed to explore the efficacy of nanosystems in treating epilepsy, AD, and PD by analyzing relevant articles from databases such as Medline, PubMed and the national library of medicine. The review discusses the targeted delivery of active therapeutics to the central nervous system, with a focus on modulating neuronal and endothelial cell activity. It highlights various nanotherapeutic approaches, including pH-responsive nanomaterial-based therapeutics, nano-bioelectronic-implantable transient electronic devices, and electro-responsive nanosystems for the treatment of epilepsy. Additionally, the efficacy of nanodrug delivery systems loaded with curcumin, monoclonal anti-tau antibody-coated gold nanoparticles, Polyethylene Glycolpolylactide-Polyglycolide (PEG-PLGA) nanoparticles loaded with lactoferrin, dopamine-conjugated Albumin/PLGA nanosystems, and curcumin-loaded T807/RPCNP nanoparticles against neurodegeneration is discussed. The findings of this review provide valuable insights into the implications and challenges of nanotherapeutics in the field of neurological diseases. Neurologists and clinicians can benefit from this knowledge to better understand the potential applications of nanotherapeutics in the diagnosis and treatment of these conditions.
{"title":"Recent advances in nanotherapeutics for epilepsy and neurodegenerative diseases","authors":"Anant R Kuchik, Rohit R Doke, Pranav P Bhor, Ritik R Matade, P. Gosavi, Akash R Shinde","doi":"10.18231/j.jpbs.2023.006","DOIUrl":"https://doi.org/10.18231/j.jpbs.2023.006","url":null,"abstract":"This review focuses on the potential of nanotherapeutics in the diagnosis and treatment of neuronal abnormal conditions particularly epilepsy, alzheimer's disease (AD), and Parkinson's disease (PD). The advancements in nanotechnology have paved the way for the development of nanocarrier systems that can target the underlying pathogenesis of these diseases. The study aimed to explore the efficacy of nanosystems in treating epilepsy, AD, and PD by analyzing relevant articles from databases such as Medline, PubMed and the national library of medicine. The review discusses the targeted delivery of active therapeutics to the central nervous system, with a focus on modulating neuronal and endothelial cell activity. It highlights various nanotherapeutic approaches, including pH-responsive nanomaterial-based therapeutics, nano-bioelectronic-implantable transient electronic devices, and electro-responsive nanosystems for the treatment of epilepsy. Additionally, the efficacy of nanodrug delivery systems loaded with curcumin, monoclonal anti-tau antibody-coated gold nanoparticles, Polyethylene Glycolpolylactide-Polyglycolide (PEG-PLGA) nanoparticles loaded with lactoferrin, dopamine-conjugated Albumin/PLGA nanosystems, and curcumin-loaded T807/RPCNP nanoparticles against neurodegeneration is discussed. The findings of this review provide valuable insights into the implications and challenges of nanotherapeutics in the field of neurological diseases. Neurologists and clinicians can benefit from this knowledge to better understand the potential applications of nanotherapeutics in the diagnosis and treatment of these conditions.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76713619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-15DOI: 10.18231/j.jpbs.2023.001
Rohit R Doke, Tejas S Naik, Disha L Lamkhade, Tanaya S Bhise, Vikrant N Khokrale, Yuvraj B Gosavi
The incidence of central nervous system (CNS) diseases is expected to rise significantly due to increasing lifespan and changing population demographics. Among CNS diseases, neurodegenerative diseases (ND’s) entail a significant challenge since they frequently involve neuronal loss and age-related progressive deterioration in brain function. Although the mechanisms and pathogenesis of neuronal disorders including Parkinson's disease (PD), Alzheimer's disease, and Huntington's disease (HD) have been extensively studied, effective treatment strategies remain limited. Drug delivery to the CNS is particularly challenging and poses a significant obstacle in the management of neurodegeneration. The present review focuses on the challenges associated with neuronal disorders, especially concerning the delivery of macro molecules containing proteins and nucleic acid. Additionally, we highlight opportunities to enhance therapeutic delivery for the treatment of ND’s. As our understanding of the biological aspects of ND’s continues to grow, there is a growing potential for therapeutic interventions. Therefore, these delivery strategies play a vital role for the future transition of CNS therapies from research labs to clinical practices.
{"title":"Novel therapeutic delivery for neurodegenerative diseases: Strategies to overcome CNS barriers","authors":"Rohit R Doke, Tejas S Naik, Disha L Lamkhade, Tanaya S Bhise, Vikrant N Khokrale, Yuvraj B Gosavi","doi":"10.18231/j.jpbs.2023.001","DOIUrl":"https://doi.org/10.18231/j.jpbs.2023.001","url":null,"abstract":"The incidence of central nervous system (CNS) diseases is expected to rise significantly due to increasing lifespan and changing population demographics. Among CNS diseases, neurodegenerative diseases (ND’s) entail a significant challenge since they frequently involve neuronal loss and age-related progressive deterioration in brain function. Although the mechanisms and pathogenesis of neuronal disorders including Parkinson's disease (PD), Alzheimer's disease, and Huntington's disease (HD) have been extensively studied, effective treatment strategies remain limited. Drug delivery to the CNS is particularly challenging and poses a significant obstacle in the management of neurodegeneration. The present review focuses on the challenges associated with neuronal disorders, especially concerning the delivery of macro molecules containing proteins and nucleic acid. Additionally, we highlight opportunities to enhance therapeutic delivery for the treatment of ND’s. As our understanding of the biological aspects of ND’s continues to grow, there is a growing potential for therapeutic interventions. Therefore, these delivery strategies play a vital role for the future transition of CNS therapies from research labs to clinical practices.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73519979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-15DOI: 10.18231/j.jpbs.2023.005
Rohit R Doke, Pratiksha S Kawade, S. U. Nagrik, Ganesh Lamkhade, A. Bhagwat
Parkinson's disease (PD) is a common neurodegenerative condition marked by the degeneration of dopaminergic neurons and the amassing of α-synuclein protein in Lewy bodies. Chaperone-mediated autophagy (CMA), a selective form of autophagy, has been implicated in the development of PD. Mutant GBA1, α-synuclein, UCHL1, VPS35, and LRRK2 are affected proteins in PD that impair the CMA process. CMA Dysfunction cause accumulation of PD-associated proteins such as α-synuclein and many other, including DJ-1, MEF2D, PARK7,etc resulting in mitochondrial dysfunctioning and apoptosis. The impact of gene mutations associated with PD on CMA has been observed, along with dysregulation of miRNAs targeting CMA components. Toxicant-induced PD models demonstrate that impaired CMA increases α-synuclein aggregates and neurotoxicity. Understanding the molecular mechanisms of CMA has identified potential therapeutic targets, including increasing LAMP2A levels. Several compounds and substances have shown promise in enhancing CMA and reducing α- synuclein aggregates, such as 6-aminonicotinamide, geldanamycin, metformin, and natural compounds like trehalose and caffeine. Pharmacological modulation of CMA, such as through retinoic acid derivatives, has demonstrated positive effects on reducing protein aggregates in neurodegenerative diseases. However, the specific effects of inhibiting CMA on macroautophagy remain uncertain. Overcoming challenges in studying CMA, such as developing suitable models and monitoring methods, is crucial for advancing our understanding of CMA's role in neurodegenerative diseases and developing effective therapeutic strategies. Overall, CMA emerges as a key player in the pathogenesis of PD, and targeting this selective autophagy pathway holds promise for developing novel therapies to combat neurodegenerative disorders.
{"title":"Navigating the cellular pathways: Chaperone-mediated autophagy as a targeted approach for management of parkinson's disease","authors":"Rohit R Doke, Pratiksha S Kawade, S. U. Nagrik, Ganesh Lamkhade, A. Bhagwat","doi":"10.18231/j.jpbs.2023.005","DOIUrl":"https://doi.org/10.18231/j.jpbs.2023.005","url":null,"abstract":"Parkinson's disease (PD) is a common neurodegenerative condition marked by the degeneration of dopaminergic neurons and the amassing of α-synuclein protein in Lewy bodies. Chaperone-mediated autophagy (CMA), a selective form of autophagy, has been implicated in the development of PD. Mutant GBA1, α-synuclein, UCHL1, VPS35, and LRRK2 are affected proteins in PD that impair the CMA process. CMA Dysfunction cause accumulation of PD-associated proteins such as α-synuclein and many other, including DJ-1, MEF2D, PARK7,etc resulting in mitochondrial dysfunctioning and apoptosis. The impact of gene mutations associated with PD on CMA has been observed, along with dysregulation of miRNAs targeting CMA components. Toxicant-induced PD models demonstrate that impaired CMA increases α-synuclein aggregates and neurotoxicity. Understanding the molecular mechanisms of CMA has identified potential therapeutic targets, including increasing LAMP2A levels. Several compounds and substances have shown promise in enhancing CMA and reducing α- synuclein aggregates, such as 6-aminonicotinamide, geldanamycin, metformin, and natural compounds like trehalose and caffeine. Pharmacological modulation of CMA, such as through retinoic acid derivatives, has demonstrated positive effects on reducing protein aggregates in neurodegenerative diseases. However, the specific effects of inhibiting CMA on macroautophagy remain uncertain. Overcoming challenges in studying CMA, such as developing suitable models and monitoring methods, is crucial for advancing our understanding of CMA's role in neurodegenerative diseases and developing effective therapeutic strategies. Overall, CMA emerges as a key player in the pathogenesis of PD, and targeting this selective autophagy pathway holds promise for developing novel therapies to combat neurodegenerative disorders.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88607885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-15DOI: 10.18231/j.jpbs.2023.007
U. Atneriya, Dharmendra Solanki, Komal Tikariya, Arpit Gawshinde
Talinolol is a beta1-selective adreno receptor antagonist well known for its Cardio protective and antihypertensive activity. Talinolol is a beta blocker. In biopharmaceutical classification system the drugs which come under class II are characterized by more membrane permeability, less dissolution rate. Talinolol is a poor aqueous solubility drug leads to poor bioavailability. So, the aimed of this study was to develop immediate release tablet of talinolol by solid dispersions technique using poloxamer 407 as a carrier. Poloxamer 407 is a hydrophilic synthetic block copolymer widely used as a solubility enhancer. Basically there are three methods used for solid dispersion. Melting or fusion method solvent evaporation method. Melting solvent method. Solvent Evaporation Method In this method a suitable solvent is selected which can capable of solubilizing both drug and hydrophilic carrier. The solvent evaporation technique is one of the most commonly used methods to prepare polymeric nanoparticles, more specifically drug-loaded polymeric systems, for pharmaceutical formulations. The prepared solid dispersions were evaluated for production yield percent, drug content, solubility, FTIR, and DSC study analysis. The prepared formulation of Talinolol with P407 in the ratio of 1:5 gave highest dissolution rate of 75.28% at 30min.So it can be concluded that the combination of solid dispersion technology as well as using superdisintergrants an encouraging and effective technique to prepare efficient fast dissolving tablets of Talinolol.The outcome of this investigation presents poloxamer 407 solid dispersion mediated fast dissolving tablets successfully resolve problem of slow rate of dissolution of talinolol.
{"title":"Development of fast release tablet of talinolol using fourth generation carrier of solid dispersion technique","authors":"U. Atneriya, Dharmendra Solanki, Komal Tikariya, Arpit Gawshinde","doi":"10.18231/j.jpbs.2023.007","DOIUrl":"https://doi.org/10.18231/j.jpbs.2023.007","url":null,"abstract":"Talinolol is a beta1-selective adreno receptor antagonist well known for its Cardio protective and antihypertensive activity. Talinolol is a beta blocker. In biopharmaceutical classification system the drugs which come under class II are characterized by more membrane permeability, less dissolution rate. Talinolol is a poor aqueous solubility drug leads to poor bioavailability. So, the aimed of this study was to develop immediate release tablet of talinolol by solid dispersions technique using poloxamer 407 as a carrier. Poloxamer 407 is a hydrophilic synthetic block copolymer widely used as a solubility enhancer. Basically there are three methods used for solid dispersion. Melting or fusion method solvent evaporation method. Melting solvent method. Solvent Evaporation Method In this method a suitable solvent is selected which can capable of solubilizing both drug and hydrophilic carrier. The solvent evaporation technique is one of the most commonly used methods to prepare polymeric nanoparticles, more specifically drug-loaded polymeric systems, for pharmaceutical formulations. The prepared solid dispersions were evaluated for production yield percent, drug content, solubility, FTIR, and DSC study analysis. The prepared formulation of Talinolol with P407 in the ratio of 1:5 gave highest dissolution rate of 75.28% at 30min.So it can be concluded that the combination of solid dispersion technology as well as using superdisintergrants an encouraging and effective technique to prepare efficient fast dissolving tablets of Talinolol.The outcome of this investigation presents poloxamer 407 solid dispersion mediated fast dissolving tablets successfully resolve problem of slow rate of dissolution of talinolol.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80835672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-15DOI: 10.18231/j.jpbs.2023.010
Avinash Teli, Rohit Kumar, Pooja Rathore, Vishal Kumar, Sharookh Ali
This comparative study aims to evaluate and compare the clinical management of drug-drug interactions (DDIs) in hypertensive patients with associated co-morbidities, specifically focusing on the practices in general medicine and ICU ward settings. Hypertensive patients commonly experience co-morbidities that require multiple medications, increasing the risk of DDIs and subsequent adverse events. Understanding the current evaluation and management strategies for DDIs in these patient populations is essential for optimizing patient outcomes. This research investigates the approaches employed in general medicine and ICU wards, including DDI identification, assessment, and intervention methods. By comparing these practices, the study aims to identify potential variations, challenges, and areas for improvement in DDI management across these clinical settings. The findings of this study will contribute to the development of evidence-based guidelines and recommendations for enhancing the clinical management of DDIs in hypertensive patients with co-morbidities, ultimately improving patient safety and therapeutic outcomes.
{"title":"Evaluation and clinical management of drug-drug interactions in hypertensive patients associated co-morbidities: A study in general medicine and ICU ward","authors":"Avinash Teli, Rohit Kumar, Pooja Rathore, Vishal Kumar, Sharookh Ali","doi":"10.18231/j.jpbs.2023.010","DOIUrl":"https://doi.org/10.18231/j.jpbs.2023.010","url":null,"abstract":"This comparative study aims to evaluate and compare the clinical management of drug-drug interactions (DDIs) in hypertensive patients with associated co-morbidities, specifically focusing on the practices in general medicine and ICU ward settings. Hypertensive patients commonly experience co-morbidities that require multiple medications, increasing the risk of DDIs and subsequent adverse events. Understanding the current evaluation and management strategies for DDIs in these patient populations is essential for optimizing patient outcomes. This research investigates the approaches employed in general medicine and ICU wards, including DDI identification, assessment, and intervention methods. By comparing these practices, the study aims to identify potential variations, challenges, and areas for improvement in DDI management across these clinical settings. The findings of this study will contribute to the development of evidence-based guidelines and recommendations for enhancing the clinical management of DDIs in hypertensive patients with co-morbidities, ultimately improving patient safety and therapeutic outcomes.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75372627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-15DOI: 10.18231/j.jpbs.2023.011
Saba Khan, J. Agnihotri, Sunanda R. Patil, N. Khan
Drug repurposing (DR), also known as drug repositioning, is a strategy aimed at identifying new therapeutic uses for existing drugs. It offers an effective approach to discovering or developing drug molecules with novel pharmacological or therapeutic indications. In recent years, pharmaceutical companies have increasingly embraced the drug repurposing strategy in their drug discovery and development programs, leading to the identification of new biological targets. This strategy is highly efficient, time-saving, cost-effective, and carries a lower risk of failure compared to traditional drug discovery methods. By maximizing the therapeutic value of existing drugs, drug repurposing increases the likelihood of success. It serves as a valuable alternative to the lengthy, expensive, and resource-intensive process of finding new molecular entities (NMEs) through traditional or de novo drug discovery approaches. Drug repurposing combines activity-based or experimental methods with in silico-based or computational approaches to rationally develop or identify new uses for drug molecules. It leverages the existing safety data of drugs tested in humans and redirects their application based on valid target molecules. This approach holds great promise, particularly in addressing rare, difficult-to-treat diseases, and neglected diseases. By utilizing the wealth of knowledge and resources available, drug repurposing presents an emerging strategy for optimizing the therapeutic potential of existing medicines. It offers a pathway to rapidly identify effective treatments and repurpose approved drugs for new indications, benefiting patients and healthcare systems alike.
{"title":"Drug repurposing: A futuristic approach in drug discovery","authors":"Saba Khan, J. Agnihotri, Sunanda R. Patil, N. Khan","doi":"10.18231/j.jpbs.2023.011","DOIUrl":"https://doi.org/10.18231/j.jpbs.2023.011","url":null,"abstract":"Drug repurposing (DR), also known as drug repositioning, is a strategy aimed at identifying new therapeutic uses for existing drugs. It offers an effective approach to discovering or developing drug molecules with novel pharmacological or therapeutic indications. In recent years, pharmaceutical companies have increasingly embraced the drug repurposing strategy in their drug discovery and development programs, leading to the identification of new biological targets. This strategy is highly efficient, time-saving, cost-effective, and carries a lower risk of failure compared to traditional drug discovery methods. By maximizing the therapeutic value of existing drugs, drug repurposing increases the likelihood of success. It serves as a valuable alternative to the lengthy, expensive, and resource-intensive process of finding new molecular entities (NMEs) through traditional or de novo drug discovery approaches. Drug repurposing combines activity-based or experimental methods with in silico-based or computational approaches to rationally develop or identify new uses for drug molecules. It leverages the existing safety data of drugs tested in humans and redirects their application based on valid target molecules. This approach holds great promise, particularly in addressing rare, difficult-to-treat diseases, and neglected diseases. By utilizing the wealth of knowledge and resources available, drug repurposing presents an emerging strategy for optimizing the therapeutic potential of existing medicines. It offers a pathway to rapidly identify effective treatments and repurpose approved drugs for new indications, benefiting patients and healthcare systems alike.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73585165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-15DOI: 10.18231/j.jpbs.2023.002
Pallavi B Sadgir, Pradnya R Pawar, Prachi S Jondhale, Manisha N Sharmale, Priya Ambre, P. Phalke
The Ebola virus of the Filoviridae family is the cause of Ebola virus disease (EVD), a deadly viral hemorrhagic sickness. Due to the prevalence of immigrants, the disease has become a global public health threat. The victims initially exhibit vague influenza-like symptoms before succumbing to shock and multiorgan failure. There is no established procedure for treating EVD; instead, only supportive and symptomatic therapy is used. The Ebola virus, including its clinical and oral symptoms, diagnostic tools, differential diagnoses, preventive measures, and management protocol, are thoroughly discussed in this review paper. Since then, the Ebola virus has occasionally started to infect humans, causing multiple epidemics. The expansion of the Ebola virus has resulted in the deadliest diseases for both animals and humans because of the growth of urbanization, invasion of forested areas, and intimate contact with wildlife creatures. The Ebola virus disease (EVD) has so far claimed the lives of numerous people, with an increased number of cases being seen throughout the African continent. Thus, a study was conducted to evaluate the efficacy and safety of medications approved for the treatment of EVD, trends in EVD outbreaks, morbidity and mortality among EVD patients, and other factors.
{"title":"A review on ebola virus","authors":"Pallavi B Sadgir, Pradnya R Pawar, Prachi S Jondhale, Manisha N Sharmale, Priya Ambre, P. Phalke","doi":"10.18231/j.jpbs.2023.002","DOIUrl":"https://doi.org/10.18231/j.jpbs.2023.002","url":null,"abstract":"The Ebola virus of the Filoviridae family is the cause of Ebola virus disease (EVD), a deadly viral hemorrhagic sickness. Due to the prevalence of immigrants, the disease has become a global public health threat. The victims initially exhibit vague influenza-like symptoms before succumbing to shock and multiorgan failure. There is no established procedure for treating EVD; instead, only supportive and symptomatic therapy is used. The Ebola virus, including its clinical and oral symptoms, diagnostic tools, differential diagnoses, preventive measures, and management protocol, are thoroughly discussed in this review paper. Since then, the Ebola virus has occasionally started to infect humans, causing multiple epidemics. The expansion of the Ebola virus has resulted in the deadliest diseases for both animals and humans because of the growth of urbanization, invasion of forested areas, and intimate contact with wildlife creatures. The Ebola virus disease (EVD) has so far claimed the lives of numerous people, with an increased number of cases being seen throughout the African continent. Thus, a study was conducted to evaluate the efficacy and safety of medications approved for the treatment of EVD, trends in EVD outbreaks, morbidity and mortality among EVD patients, and other factors.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"63 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75368729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-15DOI: 10.18231/j.jpbs.2023.004
A. O. Silva, Danielle Aparecida de Oliveira Marrafon, Ana Flávia Amorim, C. M. Barros, R. R. Rascado, C. S. Ceron, T. M. Reis, Márcia Helena MIranda Cardoso Podestá, Daniel Augusto de Faria Almeida, L. H. Torres, Marília Gabriella Alves Goulart Pereira
Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.
慢性疼痛影响着大约30%的世界人口。他他多可作为对常用阿片类药物反应不充分的患者的一种镇痛选择。本研究综述了他他多疼痛治疗的一般方面及其与氧化应激增加的可能关联，以及其与抗氧化物质关联的益处。搜索在Medline (Pubmed)、Scopus、Web of Science和Google学术数据库中进行，包括自2008年该药注册以来的研究。所选的文章是关于使用他他多治疗成人和老年人慢性中重度疼痛，而非癌症相关疼痛的文章。他他多是一种微阿片受体激动剂，可抑制去甲肾上腺素的再摄取。虽然他他多的不良反应比其他传统阿片类药物少，但研究表明他他多可诱导氧化应激，但尚未阐明其机制。
{"title":"Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review","authors":"A. O. Silva, Danielle Aparecida de Oliveira Marrafon, Ana Flávia Amorim, C. M. Barros, R. R. Rascado, C. S. Ceron, T. M. Reis, Márcia Helena MIranda Cardoso Podestá, Daniel Augusto de Faria Almeida, L. H. Torres, Marília Gabriella Alves Goulart Pereira","doi":"10.18231/j.jpbs.2023.004","DOIUrl":"https://doi.org/10.18231/j.jpbs.2023.004","url":null,"abstract":"Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"144 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77918224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-15DOI: 10.18231/j.jpbs.2022.015
R. Kumar, Rajat Dhariwal, Anurag Kumar, Mizuki Minata
The L. is also used as a crude medicament that mostly effected in various neurological and immunological disorders. It is also known as Ashwagandha and “Indian ginseng” in Indian region. There is a lack of information on the possible neuroprotective properties of W. somnifera root against HO- and Ab(1-42)-induced cytotoxicity, which are now targeted for innovative treatments for dementia, particularly dementia of the Alzheimer's type (AD). According to this research, we prepared an aqueous extract of dried roots of W. somnifera that possess the protective effect against Ab- aggregated fibril and HO cytotoxicity through MTT assay with the help of differentiated rat pheochromocytoma PC12 cell. The findings indicate that, in a concentration-dependent manner, pretreatment of differentiated PC12 cells with aqueous extracts of W. somnifera root strongly protects differentiated PC12 cells against both H2O2- and Ab(1-42)-induced cytotoxicity. The W. somnifera extract was examined using liquid chromatography-serial mass spectrometry in order to look into the substances that could be responsible for the effects that were seen. Withanolide derivatives, notably withaferin A, were found in abundance. These findings support the hypothesis that W. somnifera may be used ethnopharmacologically to treat oxidative stress-related cognitive and other neurodegenerative illnesses. They also show the neuroprotective activities of an aqueous extract of W. somnifera root.
{"title":"Effect of Withania Somnifera (L.) root extract's on PC12 induced by hydrogen peroxide, study","authors":"R. Kumar, Rajat Dhariwal, Anurag Kumar, Mizuki Minata","doi":"10.18231/j.jpbs.2022.015","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.015","url":null,"abstract":"The L. is also used as a crude medicament that mostly effected in various neurological and immunological disorders. It is also known as Ashwagandha and “Indian ginseng” in Indian region. There is a lack of information on the possible neuroprotective properties of W. somnifera root against HO- and Ab(1-42)-induced cytotoxicity, which are now targeted for innovative treatments for dementia, particularly dementia of the Alzheimer's type (AD). According to this research, we prepared an aqueous extract of dried roots of W. somnifera that possess the protective effect against Ab- aggregated fibril and HO cytotoxicity through MTT assay with the help of differentiated rat pheochromocytoma PC12 cell. The findings indicate that, in a concentration-dependent manner, pretreatment of differentiated PC12 cells with aqueous extracts of W. somnifera root strongly protects differentiated PC12 cells against both H2O2- and Ab(1-42)-induced cytotoxicity. The W. somnifera extract was examined using liquid chromatography-serial mass spectrometry in order to look into the substances that could be responsible for the effects that were seen. Withanolide derivatives, notably withaferin A, were found in abundance. These findings support the hypothesis that W. somnifera may be used ethnopharmacologically to treat oxidative stress-related cognitive and other neurodegenerative illnesses. They also show the neuroprotective activities of an aqueous extract of W. somnifera root.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73452482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-15DOI: 10.18231/j.jpbs.2022.012
Senthil Kumar Raju, Sabarainath Chandrasekar, Priyadharshini Vengadhajalapathy, R. Sundaram, Sangeetha Periyasamyy, Thatchayani Chinnaraj, Praveen Sekar, S. Kumar
commonly known as Annatto is a lipstick tree belonging to the family Indigenous populations in Brazil and other tropical nations have employed for a variety of therapeutic purposes which is also known as "". The essential natural apocarotenoid obtained from seeds namely bixin is broadly applied as a cosmetic and textile colorant. The carotenoids, which contribute to more than 80% of the annatto seed coat are responsible for the color orange-red. It is well known for its medicinal value and as a coloring agent. Annatto is used in food dye, body paint and the treatment of heartburn and it also reduces inflammation and blood sugar. The various parts of this plant has been reported to show many therapeutic indications like anti-bacterial, anti-hyperglycaemic, anti-histaminic, anti-diarrheal, anti-cancer, anti-inflammatory and anti-oxidant activities. Carotenoids, apocarotenoids, terpenes, terpenoids, sterols and aliphatic compounds are the main compounds found in all parts of this plant. The various annatto plant parts have been utilized in traditional medicine for both the prevention and treatment of a variety of health issues. This review aimed to report the primary evidence found in the literature, concerning the pharmacological activities and phytochemical studies related to . Regarding its application in food, cosmetics, leather, solar cells and other industries, significant research has already been done and is presently being conducted. This review demonstrates the well-studied pharmacological effect that might be relevant for the upcoming creation of a novel therapeutic medication.
{"title":"Review on phytochemical composition and pharmacological activities of Bixa orellana","authors":"Senthil Kumar Raju, Sabarainath Chandrasekar, Priyadharshini Vengadhajalapathy, R. Sundaram, Sangeetha Periyasamyy, Thatchayani Chinnaraj, Praveen Sekar, S. Kumar","doi":"10.18231/j.jpbs.2022.012","DOIUrl":"https://doi.org/10.18231/j.jpbs.2022.012","url":null,"abstract":" commonly known as Annatto is a lipstick tree belonging to the family Indigenous populations in Brazil and other tropical nations have employed for a variety of therapeutic purposes which is also known as \"\". The essential natural apocarotenoid obtained from seeds namely bixin is broadly applied as a cosmetic and textile colorant. The carotenoids, which contribute to more than 80% of the annatto seed coat are responsible for the color orange-red. It is well known for its medicinal value and as a coloring agent. Annatto is used in food dye, body paint and the treatment of heartburn and it also reduces inflammation and blood sugar. The various parts of this plant has been reported to show many therapeutic indications like anti-bacterial, anti-hyperglycaemic, anti-histaminic, anti-diarrheal, anti-cancer, anti-inflammatory and anti-oxidant activities. Carotenoids, apocarotenoids, terpenes, terpenoids, sterols and aliphatic compounds are the main compounds found in all parts of this plant. The various annatto plant parts have been utilized in traditional medicine for both the prevention and treatment of a variety of health issues. This review aimed to report the primary evidence found in the literature, concerning the pharmacological activities and phytochemical studies related to . Regarding its application in food, cosmetics, leather, solar cells and other industries, significant research has already been done and is presently being conducted. This review demonstrates the well-studied pharmacological effect that might be relevant for the upcoming creation of a novel therapeutic medication.","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82906066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：